Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
Health Secretary Matt Han**** said: "This new partnership will help supply essential rapid lateral flow tests to people all over the UK - showing the pivotal role that Scottish expertise is playing in our efforts to stop the spread of the virus.
"With one in three people with the virus having no symptoms, regular rapid testing allows us to identify cases we wouldn't otherwise find, preventing further transmission and saving lives."
https://www.bbc.co.uk/news/uk-scotland-scotland-business-56375683
This tweet is unavailable so why post it?
Lord Bethell has indirectly confirmed it is avactas test that will be produced with m Manufacturing contracts placed with both Gad and ODX.
fact.
BBC Scotland-all about AZK in France and Germany, nothing about the scottish contract awarded. Someone text/reply to BBC twitter.
Masses of buys...why sp not rising?
Quite right.
Quite right.
No they have not. See Malta Times. But it is coming as cases are rising daily there.
what if people sell at 1.10 or whatever on stop losses?
Kraken stimulus checks??
Ok. Dummer's question.
This is for ARB shares, current;y share price to sell 240p.
Regardless of your talk of whoppa cheques in the post from God knows what related platforms, anyone care to offer an opinon for the ARB share price outlooK?
Thanks.
The primary catalyst behind Synairgen’s soaring share price was the announcement that SNG001 successfully completed its phase II trials. The results of which showed a 79% reduction in the need for ventilation machines amongst patients. Needless to say, the drug shows promise. And it would seem the FDA in the US agrees as it has greenlit the treatment for fast-track approval.
Last month, Synairgen began recruiting for phase II/III trials to gather more data and target patients at home instead of in a hospital environment.
If SNG001 is approved, City analysts have forecast that total revenue for 2021 will be around £150m, some £47m of which will be profit. Comparing that to Synairgen’s current share price places the P/E ratio at 7.4. To me, that looks relatively cheap for a high-growth biotech stock.
Good to see.
So someone text the show and state that!!
Send twitter message to ITV BBC LBC Five Live science correspondents on Twitter.
Someone send the news to a BBC Science reporter who is active on Twitter, ditto ITV, Five Live , LBC etc? I don't have a Twitter acount.
*8.10 euro was the price at the time NOT the target!! Quote this!
In recent weeks it was revealed two new fund managers had already begun building positions in Novacyt as the Group revealed its mid cap strategy and the first part of their contract wins with the UK Government – one deal totalling up to £750 million. Octopus Investments had added Novacyt to their Micro-Cap Growth Fund, while Valu-Trac, the Scottish asset manager, has recently added Novacyt to their 5 year growth ‘Global Investors Fund’.
Again, re:Starbright, I understand your frustration with yourself if you don't have any ODX/sold out at say 85P and didn't buy again. This share has been a source of many emotions, I very much hope it will get to the levels of GDR. It deserves to.
This has turned out to be steady, solid, it dipped maddeningly up and down but if people held then to buy now will be very expensive...could have would have should have Gary?? I am like that with NCYT so I understand your chagrin with yourself.